| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Daratumumab |
| Brand | Darzalex® |
| Indication | For the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. |
| Assessment Process | |
| Rapid review commissioned | 31/05/2016 |
| Rapid review completed | 14/06/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 27/10/2016 |
| NCPE assessment completed | 03/03/2017 |
| NCPE assessment outcome | The cost effectiveness of daratumumab (Darzalex®) monotherapy has not been demonstrated. Therefore it is not recommended for reimbursement. |
The HSE has approved reimbursement following confidential price negotiations; April 2018.